BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33482770)

  • 1. The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making.
    Whitehead I; Irwin GW; Bannon F; Coles CE; Copson E; Cutress RI; Dave RV; Gardiner MD; Grayson M; Holcombe C; Irshad S; O'Brien C; O'Connell RL; Palmieri C; Shaaban AM; Sharma N; Singh JK; Potter S; McIntosh SA;
    BMC Cancer; 2021 Jan; 21(1):90. PubMed ID: 33482770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MARECA (national study of management of breast cancer locoregional recurrence and oncological outcomes) study: National practice questionnaire of United Kingdom multi-disciplinary decision making.
    Morgan JL; Cheng V; Barry PA; Copson E; Cutress RI; Dave R; Elsberger B; Fairbrother P; Hartup S; Hogan B; Horgan K; Kirwan CC; McIntosh SA; O'Connell RL; Patani N; Potter S; Rattay T; Sheehan L; Wyld L; Kim B;
    Eur J Surg Oncol; 2022 Jul; 48(7):1510-1519. PubMed ID: 35410760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
    Schwartz GF; Tannebaum JE; Jernigan AM; Palazzo JP
    Cancer; 2010 Mar; 116(5):1243-51. PubMed ID: 20087958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of axillary staging and management in clinically node positive breast cancer patients treated with neoadjuvant systemic therapy: Results of a survey amongst breast cancer specialists.
    Simons JM; Maaskant-Braat AJG; Luiten EJT; Leidenius MHK; van Nijnatten TJA; Boelens PG; Koppert LB; van der Pol CC; van de Velde CJH; Audisio RA; Smidt ML
    Eur J Surg Oncol; 2020 Jan; 46(1):53-58. PubMed ID: 31434617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NeST (neoadjuvant systemic therapy in breast cancer) study - Protocol for a prospective multi-centre cohort study to assess the current utilization and short-term outcomes of neoadjuvant systemic therapies in breast cancer.
    Irwin GW; Bannon F; Coles CE; Copson E; Cutress RI; Dave RV; Grayson M; Holcombe C; Irshad S; O'Brien C; O'Connell RL; Palmieri C; Shaaban AM; Sharma N; Singh J; Whitehead I; Potter S; McIntosh SA
    Int J Surg Protoc; 2019; 18():5-11. PubMed ID: 31897446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refining the Performance of Sentinel Lymph Node Biopsy Post-neoadjuvant Chemotherapy in Patients with Pathologically Proven Pre-treatment Node-positive Breast Cancer: An Update for Clinical Practice.
    El Hage Chehade H; Headon H; Kasem A; Mokbel K
    Anticancer Res; 2016 Apr; 36(4):1461-71. PubMed ID: 27069121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
    Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML
    Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
    Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy in patients with breast cancer: Does response in the breast predict axillary node response?
    Morgan C; Stringfellow TD; Rolph R; Kovacs T; Kothari A; Pinder SE; Hamed H; Sever AR
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):522-526. PubMed ID: 31740186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.
    Franceschini G; Di Leone A; Sanchez AM; D'Archi S; Terribile D; Magno S; Scardina L; Masetti R
    Ann Ital Chir; 2020; 91():465-468. PubMed ID: 32312945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
    Dubsky PC; Singer CF; Egle D; Wette V; Petru E; Balic M; Pichler A; Greil R; Petzer AL; Bago-Horvath Z; Fesl C; Meek SM; Kronenwett R; Rudas M; Gnant M; Filipits M;
    Eur J Cancer; 2020 Jul; 134():99-106. PubMed ID: 32502940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel lymph node biopsy following neoadjuvant chemotherapy: an evidence-based review and recommendations for current practice.
    Cavalcante FP; Millen EC; Novita GG; Zerwes FP; Mattar A; Machado RHS; Frasson AL
    Chin Clin Oncol; 2023 Feb; 12(1):6. PubMed ID: 36922355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
    Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
    Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating Lymphovenous Anastomosis in Clinically Node-Positive Women Receiving Neoadjuvant Chemotherapy: A Shared Decision-Making Model and Nuanced Approached to the Axilla.
    Lustig DB; Temple-Oberle C; Bouchard-Fortier A; Quan ML
    Curr Oncol; 2023 Apr; 30(4):4041-4051. PubMed ID: 37185419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
    Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
    Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine needle aspiration.
    Yu Y; Cui N; Li HY; Wu YM; Xu L; Fang M; Sheng Y
    BMC Cancer; 2016 Oct; 16(1):808. PubMed ID: 27756234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer.
    Park S; Lee JE; Paik HJ; Ryu JM; Bae SY; Lee SK; Kim SW; Nam SJ
    Clin Breast Cancer; 2017 Feb; 17(1):e19-e29. PubMed ID: 27495997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment.
    van der Heiden-van der Loo M; de Munck L; Sonke GS; van Dalen T; van Diest PJ; van den Bongard HJ; Peeters PH; Rutgers EJ
    Eur J Cancer; 2015 May; 51(8):915-21. PubMed ID: 25857549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
    Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
    Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.